- Home
- IBIO vs PRPH Comparison
IBIO vs PRPH Comparison
Compare IBIO & PRPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBIO
- PRPH
- Stock Information
- Founded
- IBIO 2008
- PRPH 1989
- Country
- IBIO United States
- PRPH United States
- Employees
- IBIO N/A
- PRPH N/A
- Industry
- IBIO Biotechnology: Pharmaceutical Preparations
- PRPH Biotechnology: Pharmaceutical Preparations
- Sector
- IBIO Health Care
- PRPH Health Care
- Exchange
- IBIO Nasdaq
- PRPH Nasdaq
- Market Cap
- IBIO 15.9M
- PRPH 15.2M
- IPO Year
- IBIO N/A
- PRPH 1997
- Fundamental
- Price
- IBIO $0.81
- PRPH $0.43
- Analyst Decision
- IBIO Strong Buy
- PRPH
- Analyst Count
- IBIO 3
- PRPH 0
- Target Price
- IBIO $4.87
- PRPH N/A
- AVG Volume (30 Days)
- IBIO 5.4M
- PRPH 4.1M
- Earning Date
- IBIO 05-02-2025
- PRPH 08-13-2025
- Dividend Yield
- IBIO N/A
- PRPH N/A
- EPS Growth
- IBIO N/A
- PRPH N/A
- EPS
- IBIO N/A
- PRPH N/A
- Revenue
- IBIO $375,000.00
- PRPH $5,845,000.00
- Revenue This Year
- IBIO $36.00
- PRPH $221.82
- Revenue Next Year
- IBIO N/A
- PRPH N/A
- P/E Ratio
- IBIO N/A
- PRPH N/A
- Revenue Growth
- IBIO 650.00
- PRPH N/A
- 52 Week Low
- IBIO $0.64
- PRPH $0.22
- 52 Week High
- IBIO $6.89
- PRPH $3.64
- Technical
- Relative Strength Index (RSI)
- IBIO 47.34
- PRPH 62.32
- Support Level
- IBIO $0.71
- PRPH $0.32
- Resistance Level
- IBIO $0.87
- PRPH $0.46
- Average True Range (ATR)
- IBIO 0.08
- PRPH 0.03
- MACD
- IBIO 0.02
- PRPH 0.01
- Stochastic Oscillator
- IBIO 37.39
- PRPH 75.57
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.